Idinvest Partners, an investor in SMEs across Europe, has arranged the unitranche financing of Keensight Capital’s acquisition of 3P Biopharmaceuticals. It is the 8th deal closed this year by Idinvest’s Private Debt team in the Iberian Peninsula.
3P Biopharmaceuticals is a leading Contract Development and Manufacturing Organization (CDMO) specialized in the process development and manufacturing of biopharmaceuticals through mammalian, microbial and yeast expression systems. 3P Biopharmaceuticals offers solutions at all developmental stages: from initial steps to analytics development, preclinical and clinical phases, and commercial production. Established in 2006 near Pamplona, Spain, the company provides a comprehensive service to a wide range of customers located in Europe, North America, Australia and Asia.
François Lacoste, Managing Partner and Co-Head of Private Debt at Idinvest Partners, says: “3P Biopharmaceuticals’ outstanding historical performance has allowed the company to reinforce its internationally focused strategy and strong customer base. 3P is one of the few European companies to offer a one-stop-shop service in the biologics sector, an extremely fast-growing market.”
